<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706836</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD IRB 060407 - B</org_study_id>
    <secondary_id>R01MH075792</secondary_id>
    <nct_id>NCT00706836</nct_id>
  </id_info>
  <brief_title>PharmacofMRI of Anxiolytic Medications (Pregabalin)</brief_title>
  <official_title>PharmacofMRI of Anxiolytic Medications (Pregabalin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy
      controls to examine the acute effects of certain anxiolytic medications on brain function. In
      this case, the medication pregabalin will be used. The investigators hypothesize that
      pregabalin (at doses of 50 mg and 200 mg, versus placebo) will yield a reduction in amygdala
      and insula activity (in a dose-dependent fashion) during emotion processing using fMRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increased amygdala and insula activity have been implicated in neurobiological models of
      anxiety. Using fMRI, the anxiolytic medication, lorazepam, has previously been found to
      decrease activation in these areas during the processing of emotional stimuli. This study
      aims to replicate those results but by using a different medication, pregabalin. An eventual
      aim of this study, in combination with future studies, is to evaluate the utility of fMRI as
      a tool to identify anxiolytic function in both established and novel compounds that may be
      used to treat anxiety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Pregabalin (Two Doses) Versus Placebo</measure>
    <time_frame>Week 1, 2, 3 (Cross-over Design)</time_frame>
    <description>Region of Interest (ROI) analysis of contrast of doses (high and low) of pregabalin vs placebo on brain activity at rest and during emotional stimuli using fMRI and clinical scales.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Effects of an Anxiolytic Drug Versus Placebo on Eye Blink Startle Response at Rest and During Emotional Stimuli (Anxiety Potentiated Startle, APS) as Well as on Clinical Scales.</measure>
    <time_frame>Week 1, 2, 3</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Pregabalin 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregabalin oral tablets (50 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregabalin oral tablets (200 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan</description>
    <arm_group_label>Pregabalin 50 mg</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan</description>
    <arm_group_label>Pregabalin 200 mg</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>One dose of matched oral placebo to be administered one hour prior to fMRI scan</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, or female (not pregnant or intending to become pregnant during the study)

          -  Between the ages of 18-30.

          -  In good general health.

          -  No specific contraindications to the drug being administered

        Exclusion Criteria:

          -  Subjects with a history of DSM-IV depressive disorder, psychotic disorder, anxiety
             disorder

          -  Subjects who meet criteria for substance abuse or dependence within the last 6 months

          -  Subjects with an positive urine screen for illicit drugs having clinically significant
             abnormal laboratory, ECG or physical examination findings not resolved by the baseline
             visit

          -  Patients who have taken psychotropic drugs or antidepressants (including monoamine
             oxidase inhibitors, MAOI's) within the last year

          -  Subjects who are left-handed.

          -  Subjects suffering suffers from claustrophobia, or phobia for injections or blood

          -  Magnetic Resonance Imaging related exclusion criteria: cardiac pacemaker, metal
             fragments in eyes/skin/body (shrapnel), subjects who have ever been a metal
             worker/welder; history of eye surgery/eyes washed out because of metal,
             aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid,
             heart valve replacement, subjects who are in the first trimester of pregnancy,
             subjects with an I.U.D. (birth control device), a shunt (ventricular or spinal),
             electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray B Stein, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Aupperle RL, Ravindran L, Tankersley D, Flagan T, Stein NR, Simmons AN, Stein MB, Paulus MP. Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuropsychopharmacology. 2011 Jun;36(7):1466-77. doi: 10.1038/npp.2011.32. Epub 2011 Mar 23.</citation>
    <PMID>21430645</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2008</study_first_posted>
  <results_first_submitted>December 3, 2014</results_first_submitted>
  <results_first_submitted_qc>December 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2014</results_first_posted>
  <last_update_submitted>December 19, 2014</last_update_submitted>
  <last_update_submitted_qc>December 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Murray B. Stein</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>anxiety</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <keyword>fMRI</keyword>
  <keyword>pregabalin</keyword>
  <keyword>Lyrica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Anti-Anxiety Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy subjects recruited by posted advertisements.</recruitment_details>
      <pre_assignment_details>Subjects determined to be healthy based on physical examination, mental health examination, and routine bloodwork.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Pregabalin oral tablets (50 mg) Pregabalin oral tablets (200 mg) Placebo
All participants received all 3 treatments on different days.
Sequence not available.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>16 healthy subjects (10 male; mean age=23.2Â±2.6)</population>
      <group_list>
        <group group_id="B1">
          <title>All 3 Treatments (Cross-Over Design)</title>
          <description>Pregabalin oral tablets (50 mg) Pregabalin oral tables (200 mg) Placebo
All subjects received all 3 treatments on different days.
Sequence data not available.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Pregabalin (Two Doses) Versus Placebo</title>
        <description>Region of Interest (ROI) analysis of contrast of doses (high and low) of pregabalin vs placebo on brain activity at rest and during emotional stimuli using fMRI and clinical scales.</description>
        <time_frame>Week 1, 2, 3 (Cross-over Design)</time_frame>
        <population>Cross-over design, complete data available for all participants. Total number of participants in study is 16; all subjects received all 3 arms of treatment in randomized order.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin Low Dose (Crossover)</title>
            <description>Pregabalin oral tablets (50 mg)
pregabalin: One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan</description>
          </group>
          <group group_id="O2">
            <title>Pregabalin High Dose (Crossover)</title>
            <description>Pregabalin oral tablets (200 mg)
pregabalin: One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Crossover)</title>
            <description>Placebo
placebo: One dose of matched oral placebo to be administered one hour prior to fMRI scan</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Pregabalin (Two Doses) Versus Placebo</title>
          <description>Region of Interest (ROI) analysis of contrast of doses (high and low) of pregabalin vs placebo on brain activity at rest and during emotional stimuli using fMRI and clinical scales.</description>
          <population>Cross-over design, complete data available for all participants. Total number of participants in study is 16; all subjects received all 3 arms of treatment in randomized order.</population>
          <units>% signal change L amygdala + anticipn</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.2"/>
                    <measurement group_id="O2" value="-0.1" spread="0.1"/>
                    <measurement group_id="O3" value="0.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Effects of an Anxiolytic Drug Versus Placebo on Eye Blink Startle Response at Rest and During Emotional Stimuli (Anxiety Potentiated Startle, APS) as Well as on Clinical Scales.</title>
        <time_frame>Week 1, 2, 3</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Acute within 2 hours of administration</time_frame>
      <desc>Single dose acute adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin Low Dose (Crossover)</title>
          <description>Pregabalin oral tablets (50 mg)
pregabalin: One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan</description>
        </group>
        <group group_id="E2">
          <title>Pregabalin High Dose (Crossover)</title>
          <description>Pregabalin oral tablets (200 mg)
pregabalin: One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Crossover)</title>
          <description>Placebo
placebo: One dose of matched oral placebo to be administered one hour prior to fMRI scan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Dizziness or lightheadedness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Murray B. Stein MD, MPH</name_or_title>
      <organization>University of California San Diego</organization>
      <phone>858-534-6400</phone>
      <email>mstein@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

